Glucose-deprivation increases thyroid cancer cells sensitivity to metformin

Abstract

Metformin inhibits thyroid cancer cell growth. We sought to determine if variable glucose concentrations in medium alter the anti-cancer efficacy of metformin. Thyroid cancer cells (FTC133 and BCPAP) were cultured in high-glucose (20 mM) and low-glucose (5 mM) medium before treatment with metformin. Cell viability and apoptosis assays were performed. Expression of glycolytic genes was examined by real-time PCR, western blot, and immunostaining. Metformin inhibited cellular proliferation in high-glucose medium and induced cell death in low-glucose medium. In low-, but not in high-glucose medium, metformin induced endoplasmic reticulum stress, autophagy, and oncosis. At micromolar concentrations, metformin induced phosphorylation of AMP-activated protein kinase and blocked p-pS6 in low-glucose medium. Metformin increased the rate of glucose consumption from the medium and prompted medium acidification. Medium supplementation with glucose reversed metformin-inducible morphological changes. Treatment with an inhibitor of glycolysis (2-deoxy-D-glucose (2-DG)) increased thyroid cancer cell sensitivity to metformin. The combination of 2-DG with metformin led to cell death. Thyroid cancer cell lines were characterized by over-expression of glycolytic genes, and metformin decreased the protein level of pyruvate kinase muscle 2 (PKM2). PKM2 expression was detected in recurrent thyroid cancer tissue samples.In conclusion, we have demonstrated that the glucose concentration in the cellular milieu is a factor modulating metformin's anti-cancer activity. These data suggest that the combination of metformin with inhibitors of glycolysis could represent a new strategy for the treatment of thyroid cancer.

Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism

“…Metformin has been reported to inhibit the cell growth and reverse the drug-resistance in some cancers by reducing the production of ATP [ 38 , 39 ]. In addition, although metformin has been reported to increase chemosensitivity and target PKM2 in routine cancer cells [ 40 , 41 ], effect of metformin on cancer models with acquired drug resistance is unclear. In the present study, we demonstrated that metformin treatment decreased the expression of PKM2 in carboplatin-resistant NSCLC cells.…”

Cpt1c regulated by AMPK promotes papillary thyroid carcinomas cells survival under metabolic stress conditions

“…Thyroid cancer, as the most common endocrine malignancy, has a rapidly increasing incidence in world-wide recently 12 . PTC, as the most common type of thyroid cancer, accounts for 70-90 % of all thyroid malignancies 13 .…”

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo

“…Interestingly, we observed a differential susceptibility of different thyroid cancer cell lines to the antiproliferative effects of metformin, and showed that the availability of metabolic substrates (i.e. glucose) modifies the response to metformin in vitro (15). This observation formed the rationale to test the role of mGPDH in growth and metabolism of thyroid cancer cell lines in vitro , metastatic mouse models in vivo and in a transgenic mouse model that spontaneously develops thyroid cancer.…”